Dear Contractor

CPNI wishes to bring to your attention the recently updated criteria and application forms for the NICPLD Independent Prescribing course, which are available here on the NICPLD website.  Contractors will be aware that planned reforms to the initial education and training of pharmacy students in Northern Ireland will mean that all pharmacists successfully joining the register from 2026 onwards will be annotated as Independent Prescribers.  Those pharmacists already on the register or joining the register prior to 2026 may obtain IP status and annotation by successfully completing a recognised IP training course such as that provided by NICPLD.

CPNI is aware that the numbers of community pharmacists obtaining places on IP courses in Northern Ireland in previous years has been significantly lower than those from the Hospital and General Practice sectors.  Recent changes to the application criteria are hoped to improve access for community pharmacists and as such contractors and their teams may find the updated application information to be of interest.  Applications for those trainees hoping to commence the course in August/September 2023 will be accepted by email to nicpld-prescribing@qub.ac.uk from Monday 16 January 2023 with a closing date of Monday 6 March 2023.

SUMMARY

Information on the 2023/24 NICPLD Independent Prescribing course includes:

  • This course (Post Graduate Certificate level) is divided into four modules and runs over an eight-month period.
  • It includes 400 hours of learning time commitment plus 90 hours learning in practice.
  • The pharmacist may complete their learning in practice at any point during the eight-month period.
  • There will be approximately 8 compulsory workshop/assessment days which are likely to be conducted via zoom.  Approximate dates are available on pages 7-8 of the trainee information booklet.

Changes to eligibility for the NICPLD Independent Prescribing course include:

  • Prior to 2022, to be eligible for acceptance onto the course, pharmacists must have been practising for at least two years post registration and be able to produce evidence of clinical and therapeutic experience in their intended prescribing area.
  • However, from Cohort 17 (starts Aug/Sept 2023), applicants no longer need to adhere to these criteria. 
  • Previously the Designated Prescriber Practitioner (DPP) was required to be a medical Doctor.  The DPP can now be a non-medical prescriber.

As such, the criteria for applicants for the 2023 intake are:

  1. Current registration with GPhC/PSNI and be in good standing with them, or any other healthcare regulator with which they are registered
  2. Must have relevant patient-orientated experience in a UK (not ROI/elsewhere) pharmacy setting and be able to recognise, understand and articulate the skills and attributes required by a prescriber to act as the foundation of their prescribing practice whilst training
  3. Must identify an area of clinical or therapeutic practice on which to base their learning, for the purposes of developing their independent prescribing practice
  4. A Designated Prescribing Practitioner (DPP) who has agreed to supervise their learning in practice. This named practitioner must be registered with and be in good standing with their healthcare professional body in Great Britain or Northern Ireland, have legal Independent Prescribing rights and have:
    • Active prescribing competence in the areas in which they will be supervising;
    • Appropriate patient-facing clinical and diagnostic skills;
    • Supported or supervised other healthcare professionals, and
    • The ability to assess patient-facing clinical and diagnostic skills.

ACTION

Contractors are advised to:

Please contact a member of the CPNI team should you have any queries.

Kind regards

SENT ON BEHALF OF
GERARD GREENE
Chief Executive
This update contains important information for community pharmacy teams, including details of the ongoing response to the COVID-19 pandemic.

BSO ALERTS

CPNI ALERTS

DOH(NI) ALERTS

Pharmacy team(s) can keep updated via CPNI’s Contractor Calendar and Contractor Emails.
Or report medicine shortages, pricing and staffing issues via the CPNI’s Medicine Shortage Reporter and Situation Reporter.
Please bring this to the attention of your pharmacy team(s).

Kind regards

SENT ON BEHALF OF 
DR. GARETH C. GILVARY
Governance & Support Pharmacist

Dear Contractor

CPNI understands that BSO will begin processing the grant funding allocation payments for your PMR DM+D clinical system amendments to Contractors at the end of January 2023.

ACTION

Contractors are advised to:

  • Note the correspondence issued by SPPG Pharmacy & Medicines Management team in relation to this; and
  • Complete and submit the claim form at Appendix A to your local SPPG Primary Care Office, if not already done, as soon as is practically possible.

Please contact a member of the CPNI team should you have any queries.

Kind regards

SENT ON BEHALF OF
GERARD GREENE
Chief Executive
Dear Colleague
The final update of concessionary prices were granted today for December 2022:
DrugPack SizeConcessionary Price
Gabapentin 600mg tablets100£40.25
Levetiracetam 100mg/ml oral solution sugar free300£14.18
Mebeverine 135mg tablets100£6.39
Nitrofurantoin 50mg tablets28£13.86
Concessionary prices will be paid against the usual code, no additional endorsements are needed.
Please continue to notify CPNI of any pricing issues you are experiencing via our new Medicine Shortage Reporter.

Concessionary prices are also published on the CPNI website.

Kind regards

SENT ON BEHALF OF
GERARD GREENE
Chief Executive
Dear Contractor
BSO has forwarded correspondence issued by DHSC (updated on 28 December 2022) in respect of the supply of antibiotics for the treatment of Group A Strep 
HERE.

The update summarises the supply position as of 28 December 2022; highlights current SSPs and key issues in respect of decision pathways; provides supporting clinical information; and provides links and references.

ACTION

Contractors are advised to:

  • Note the update issued by DHSC and bring this to the attention of their dispensing teams; and
  • Keep this information for future reference.

Kind regards

SENT ON BEHALF OF
GERARD GREENE
Chief Executive
Dear Contractor
The Department of Health NI has issued guidance (14 November 2022) on professional and legal responsibilities in respect of the supply of medicines against private prescriptions HERE.

SUMMARY

The guidance provides information relating to:

  • Requirements for prescriptions: general
  • Requirements for prescriptions: approved country health professionals
  • Electronic Prescriptions: UK prescribers
  • Electronic Prescriptions: approved country health professionals
  • Other Regulatory Bodies
  • Validity of prescriptions
  • Supplying Medicines on Prescription

ACTION

Contractors are advised to:

  • Note the contents of the guidance and bring it to the attention of dispensary teams; and
  • Keep the guidance for future reference.

Kind regards – Mike

SENT ON BEHALF OF
PROF. MIKE MAWHINNEY
Head of Regulatory Affairs